Concomitant occurrence of blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukaemia after lenalidomide treatment for del(5q) myelodysplastic syndrome

Nicola S. Fracchiolla, Alessanda Iurlo, Valeria Ferla, Bruno Fattizzo, Alessandra Freyrie, Gianluigi Reda, Agostino Cortelezzi

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Myelodysplastic syndromes with chromosome 5 long arm deletion (5q-MDS) may benefit from lenalidomide treatment. However, unresponsive patients have a high risk for clonal evolution and progression to acute myeloid leukemia. Case: We describe a 5q-patient treated with lenalidomide, who concomitantly developed acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm, a rare and highly aggressive lymphoma. Conclusions: Evolution of 5q-syndrome to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm may have occurred through various mechanisms, including persistence of neoplastic lenalidomide-resistant stem cells and selection of a more aggressive clone via lenalidomide augmentation of the ARPC1B gene, or because of lenalidomide stimulation on dendritic cells. Further studies are needed to clarify lenalidomide oncogenic potential.

Original languageEnglish
Pages (from-to)1513-1517
Number of pages5
JournalClinical Laboratory
Volume63
Issue number9
DOIs
Publication statusPublished - 2017

Keywords

  • Acute myeloid leukaemia
  • Blastic plasmacytoid dendritic cell neoplasm
  • Lenalidomide
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Concomitant occurrence of blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukaemia after lenalidomide treatment for del(5q) myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this